e-learning
resources
Virtual 2020
Pre-Congress Content
Monoclonal antibodies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ABPA relapse after discontinuation of omalizumab
C. Bucca (Torino (TO), Italy), L. Brussino (Torino (TO), Italy), I. Ridolfi (Torino (TO), Italy), S. Nicola (Torino (TO), Italy), G. Rolla (Torino (TO), Italy)
Source:
Virtual Congress 2020 – Monoclonal antibodies in asthma
Session:
Monoclonal antibodies in asthma
Session type:
E-poster session
Number:
2223
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Bucca (Torino (TO), Italy), L. Brussino (Torino (TO), Italy), I. Ridolfi (Torino (TO), Italy), S. Nicola (Torino (TO), Italy), G. Rolla (Torino (TO), Italy). ABPA relapse after discontinuation of omalizumab. 2223
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Source: Eur Respir J 2014; 43: 602-609
Year: 2013
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018
Year: 2018
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
The effectiveness of omalizumab in steroid-dependent asthma patients
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019
Year: 2020
A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma
Source: Eur Respir J, 52 (3) 1801159; 10.1183/13993003.01159-2018
Year: 2018
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept